NATCO PHARMA
|
NATCO PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 105.33 | 77.56 | 39.19 | 9.32 | 24.16 |
| CEPS(Rs) | 118.36 | 87.99 | 48.17 | 17.13 | 30.65 |
| DPS(Rs) | 6.00 | 9.50 | 5.50 | 4.50 | 5.25 |
| Book NAV/Share(Rs) | 424.97 | 326.99 | 267.06 | 233.44 | 224.88 |
| Tax Rate(%) | 17.81 | 17.04 | 17.01 | 15.92 | 23.67 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 46.05 | 40.43 | 31.64 | 11.89 | 28.97 |
| EBIT Margin(%) | 48.60 | 39.08 | 30.42 | 9.92 | 28.45 |
| Pre Tax Margin(%) | 48.10 | 38.63 | 29.91 | 9.12 | 27.81 |
| PAT Margin (%) | 39.54 | 32.05 | 24.83 | 7.67 | 21.23 |
| Cash Profit Margin (%) | 44.47 | 36.36 | 30.51 | 14.10 | 26.84 |
| Performance Ratios | |||||
| ROA(%) | 24.35 | 22.13 | 13.29 | 3.43 | 9.43 |
| ROE(%) | 27.98 | 25.88 | 15.66 | 4.06 | 11.27 |
| ROCE(%) | 32.85 | 30.08 | 18.06 | 4.86 | 13.99 |
| Asset Turnover(x) | 0.62 | 0.69 | 0.54 | 0.45 | 0.44 |
| Sales/Fixed Asset(x) | 1.25 | 1.24 | 0.89 | 0.76 | 0.86 |
| Working Capital/Sales(x) | 1.10 | 1.42 | 1.24 | 1.25 | 1.15 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.80 | 0.81 | 1.13 | 1.32 | 1.16 |
| Receivable days | 93.30 | 86.16 | 93.53 | 85.10 | 84.44 |
| Inventory Days | 56.17 | 60.81 | 95.32 | 128.47 | 118.77 |
| Payable days | 145.20 | 136.43 | 133.18 | 106.38 | 151.52 |
| Valuation Parameters | |||||
| PER(x) | 7.57 | 12.27 | 14.38 | 81.30 | 34.16 |
| PCE(x) | 6.74 | 10.81 | 11.70 | 44.21 | 26.92 |
| Price/Book(x) | 1.88 | 2.91 | 2.11 | 3.24 | 3.67 |
| Yield(%) | 0.75 | 1.00 | 0.98 | 0.59 | 0.64 |
| EV/Net Sales(x) | 2.79 | 4.11 | 3.66 | 7.21 | 7.33 |
| EV/Core EBITDA(x) | 4.85 | 8.75 | 9.52 | 38.67 | 21.19 |
| EV/EBIT(x) | 5.35 | 9.71 | 11.30 | 63.75 | 25.37 |
| EV/CE(x) | 1.57 | 2.65 | 1.97 | 3.00 | 3.43 |
| M Cap / Sales | 3.22 | 4.26 | 3.80 | 7.11 | 7.34 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 10.77 | 47.72 | 39.20 | -5.23 | 7.16 |
| Core EBITDA Growth(%) | 35.70 | 80.69 | 186.95 | -48.93 | 2.87 |
| EBIT Growth(%) | 36.78 | 93.14 | 298.54 | -62.91 | 0.46 |
| PAT Growth(%) | 35.66 | 94.09 | 320.76 | -61.57 | -3.43 |
| EPS Growth(%) | 35.81 | 97.88 | 320.76 | -61.44 | -4.58 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.04 | 0.06 | 0.03 | 0.09 | 0.06 |
| Current Ratio(x) | 5.59 | 4.14 | 4.39 | 3.50 | 4.46 |
| Quick Ratio(x) | 4.77 | 3.47 | 3.35 | 2.49 | 3.04 |
| Interest Cover(x) | 96.87 | 88.16 | 60.44 | 12.42 | 44.58 |
| Total Debt/Mcap(x) | 0.02 | 0.02 | 0.02 | 0.03 | 0.02 |
Compare Financial Ratios of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹15,730.4 Cr | 4.3% | 6% | -34.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹439,378.0 Cr | 2.8% | 6.7% | 2.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹171,996.0 Cr | 1.9% | -0.5% | 6.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹125,959.0 Cr | 0.1% | 3.4% | 15.8% | Stock Analytics | |
| CIPLA | ₹123,666.0 Cr | 1.8% | -3.2% | 2.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹105,008.0 Cr | 2.7% | 0.4% | 3.4% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | 4.3% |
6% |
-34.9% |
| SENSEX | 0.6% |
1.3% |
7% |
You may also like the below Video Courses
